DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-087/S-013

Hoffmann-La Roche, Inc.
Attention: Duane L. Voss
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Ms. Voss:

Please refer to your supplemental new drug application dated November 1, 2002, received November 4, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for TAMIFLU® (oseltamivir phosphate) Capsules, 75 mg.

This "Changes Being Effected in 30 days" supplemental new drug application provides for use of the Roche, Nutley facility as an additional analytical testing site for stability testing of Tamiflu capsules.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Sean J. Belouin, R.Ph., Regulatory Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Stephen P. Miller, Ph.D.
Chemistry Team Leader for the
Division of Antiviral Drug Products, (HFD-530)
DNDC III, Office of New Drug Chemistry
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Stephen Paul Miller
3/10/03 04:09:16 PM
NDA 21-087 S-013 is approved